Please go to the PowerPak homepage
and select a course.
COVID-19: Keeping Up with a Moving Target – Session 4
This educational activity is jointly provided by the Postgraduate Institute for Medicine and DKBmed, LLC.
Supported by independent educational grants from Regeneron Pharmaceuticals, Inc.
Cindy Zoellner, PharmD, BCPS-AQID
Senior Clinical Pharmacy Specialist in HIV and HCV
Clinical Associate Professor Department of Internal Medicine, Division of Infectious Diseases
UT Southwestern Medical Center at Dallas
Michael Angarone, DO
Division of Infectious Diseases
Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Cindy Zoellner, PharmD, BCPS-AQID has no actual or potential conflicts of interest in relation to this program.
Michael Angarone, DO has reported the following: Speakers' Bureau—Allergan.
The PIM planners and others have nothing to disclose. The DKBmed planners and others have nothing to disclose.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed, LLC. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), and the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for .5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-21-2646-H01-P
Type of Activity: Knowledge
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 30 minutes
June 30, 2021
July 31, 2021
This accredited activity has been designed for managed care pharmacists, medical directors, pharmacy directors, pharmacy benefit managers, and other formulary decision-makers involved in the treatment decision-making process for patients with COVID-19.
How to Earn Credit
Participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
To educate pharmacists with the most up-to-date information on COVID-19 treatments and management.
Upon completion of this educational activity, participants should be better able to:
- Discuss immunological and virological concepts as they relate to COVID-19 pathophysiology and new and in-development treatments.
- Describe current management strategies for mild to moderate COVID-19.
- Evaluate treatment regimens for patients with COVID-19 requiring hospitalization.
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
On June 25, the FDA announced that the monoclonal antibody combination of bamlanivimab/etesevimab is being temporarily held from distribution on a national basis until further notice. The CDC has identified that the combined frequencies of the SARS-CoV-2 P.1/Gamma variant and the B.1.351/Beta variant = throughout the United States now exceed 11% and are trending upward. Results from in vitro assays that are used to assess the susceptibility of viral variants to particular monoclonal antibodies suggest that bamlanivimab and etesevimab administered together are not active against either the P.1 or B.1.351 variants.
The monoclonal antibody sotrovimab and the combination of casirivimab/imdevimab are both currently authorized and both are likely to retain activity against P.1 or B.1.351 variants.
In addition, the IDSA has updated its guidance and now includes sotrovimab among recommended neutralizing antibodies.
As usual, to keep track of updates, please review the following websites:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.